Silverberg Bernstein Capital Management LLC Lowers Position in NeoGenomics, Inc. (NASDAQ:NEO)

Silverberg Bernstein Capital Management LLC decreased its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 15.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 21,180 shares of the medical research company’s stock after selling 4,000 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in NeoGenomics were worth $349,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. State Street Corp lifted its position in NeoGenomics by 1.6% during the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock valued at $73,139,000 after acquiring an additional 80,449 shares during the last quarter. First Light Asset Management LLC raised its stake in shares of NeoGenomics by 14.5% in the second quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock worth $52,464,000 after purchasing an additional 480,396 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of NeoGenomics by 7.0% during the second quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company’s stock worth $46,108,000 after purchasing an additional 217,687 shares during the period. American Century Companies Inc. boosted its position in NeoGenomics by 5.4% in the second quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company’s stock valued at $45,241,000 after buying an additional 167,145 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in NeoGenomics by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock worth $45,022,000 after buying an additional 36,136 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Insider Transactions at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the company’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares in the company, valued at $570,301.44. This represents a 12.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company’s stock.

NeoGenomics Trading Up 16.5 %

NEO stock opened at $16.05 on Wednesday. NeoGenomics, Inc. has a 12-month low of $12.13 and a 12-month high of $19.11. The business’s 50-day moving average is $16.77 and its 200 day moving average is $15.67. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -26.31 and a beta of 1.24.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.06) earnings per share. On average, sell-side analysts anticipate that NeoGenomics, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on NEO shares. Bank of America upped their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a research note on Friday, January 10th. Finally, Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.30.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.